Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells

Fig. 3

Oxaliplatin dose- and time-dependently reduces the NAD+/NADH ratio in HCT116 p53-wild-type (a) and p53-null (b) cells. Cells were treated with ddH2O or oxaliplatin, and the NAD+ and NADH levels in cell extracts were quantified based on the optical density at 450 nm, the NAD+/NADH ratio was calculated. Values (mean ± SEs) were obtained from at least three independent experiments

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us